367 related articles for article (PubMed ID: 34504076)
21. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.
Rubinson DA; Tanaka N; Fece de la Cruz F; Kapner KS; Rosenthal MH; Norden BL; Barnes H; Ehnstrom S; Morales-Giron AA; Brais LK; Lemke CT; Aguirre AJ; Corcoran RB
Cancer Discov; 2024 May; 14(5):727-736. PubMed ID: 38236605
[TBL] [Abstract][Full Text] [Related]
22. Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay.
Swiatnicki M; Engel L; Shrestha R; Alves J; Goueli SA; Zegzouti H
SLAS Discov; 2022 Jun; 27(4):249-257. PubMed ID: 35288294
[TBL] [Abstract][Full Text] [Related]
23. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.
Lito P; Solomon M; Li LS; Hansen R; Rosen N
Science; 2016 Feb; 351(6273):604-8. PubMed ID: 26841430
[TBL] [Abstract][Full Text] [Related]
24. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
25. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
26. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
27. Targeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function.
Kattan WE; Chen W; Ma X; Lan TH; van der Hoeven D; van der Hoeven R; Hancock JF
Life Sci Alliance; 2019 Oct; 2(5):. PubMed ID: 31451509
[TBL] [Abstract][Full Text] [Related]
28. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Canon J; Rex K; Saiki AY; Mohr C; Cooke K; Bagal D; Gaida K; Holt T; Knutson CG; Koppada N; Lanman BA; Werner J; Rapaport AS; San Miguel T; Ortiz R; Osgood T; Sun JR; Zhu X; McCarter JD; Volak LP; Houk BE; Fakih MG; O'Neil BH; Price TJ; Falchook GS; Desai J; Kuo J; Govindan R; Hong DS; Ouyang W; Henary H; Arvedson T; Cee VJ; Lipford JR
Nature; 2019 Nov; 575(7781):217-223. PubMed ID: 31666701
[TBL] [Abstract][Full Text] [Related]
29. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
[TBL] [Abstract][Full Text] [Related]
30. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.
Kirschner T; Müller MP; Rauh D
J Med Chem; 2024 Apr; 67(8):6044-6051. PubMed ID: 38621359
[TBL] [Abstract][Full Text] [Related]
31. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
Sato M; Larsen JE; Lee W; Sun H; Shames DS; Dalvi MP; Ramirez RD; Tang H; DiMaio JM; Gao B; Xie Y; Wistuba II; Gazdar AF; Shay JW; Minna JD
Mol Cancer Res; 2013 Jun; 11(6):638-50. PubMed ID: 23449933
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a Covalent Inhibitor of KRAS
Lanman BA; Allen JR; Allen JG; Amegadzie AK; Ashton KS; Booker SK; Chen JJ; Chen N; Frohn MJ; Goodman G; Kopecky DJ; Liu L; Lopez P; Low JD; Ma V; Minatti AE; Nguyen TT; Nishimura N; Pickrell AJ; Reed AB; Shin Y; Siegmund AC; Tamayo NA; Tegley CM; Walton MC; Wang HL; Wurz RP; Xue M; Yang KC; Achanta P; Bartberger MD; Canon J; Hollis LS; McCarter JD; Mohr C; Rex K; Saiki AY; San Miguel T; Volak LP; Wang KH; Whittington DA; Zech SG; Lipford JR; Cee VJ
J Med Chem; 2020 Jan; 63(1):52-65. PubMed ID: 31820981
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels.
Bojjireddy N; Botyanszki J; Hammond G; Creech D; Peterson R; Kemp DC; Snead M; Brown R; Morrison A; Wilson S; Harrison S; Moore C; Balla T
J Biol Chem; 2014 Feb; 289(9):6120-32. PubMed ID: 24415756
[TBL] [Abstract][Full Text] [Related]
34. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T
Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772
[TBL] [Abstract][Full Text] [Related]
35. Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer.
Maroni G; Bassal MA; Krishnan I; Fhu CW; Savova V; Zilionis R; Maymi VA; Pandell N; Csizmadia E; Zhang J; Storti B; Castaño J; Panella R; Li J; Gustafson CE; Fox S; Levy RD; Meyerovitz CV; Tramontozzi PJ; Vermilya K; De Rienzo A; Crucitta S; Bassères DS; Weetall M; Branstrom A; Giorgetti A; Ciampi R; Del Re M; Danesi R; Bizzarri R; Yang H; Kocher O; Klein AM; Welner RS; Bueno R; Magli MC; Clohessy JG; Ali A; Tenen DG; Levantini E
Commun Biol; 2021 Apr; 4(1):370. PubMed ID: 33854168
[TBL] [Abstract][Full Text] [Related]
36. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
[TBL] [Abstract][Full Text] [Related]
37. Nonclinical Safety Profile of Sotorasib, a KRAS
Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
[TBL] [Abstract][Full Text] [Related]
38. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
39. An Inhibitor of the Pleckstrin Homology Domain of CNK1 Selectively Blocks the Growth of Mutant KRAS Cells and Tumors.
Indarte M; Puentes R; Maruggi M; Ihle NT; Grandjean G; Scott M; Ahmed Z; Meuillet EJ; Zang S; Lemos R; Du-Cuny L; Layng FIAL; Correa RG; Bankston LA; Liddington RC; Kirkpatrick L; Powis G
Cancer Res; 2019 Jun; 79(12):3100-3111. PubMed ID: 31040156
[TBL] [Abstract][Full Text] [Related]
40. Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.
Shimomura I; Watanabe N; Yamamoto T; Kumazaki M; Tada Y; Tatsumi K; Ochiya T; Yamamoto Y
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]